CBS 2019
CBSMD教育中心
中 文

肺动脉高压

Abstract

Recommended Article

Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease Left main coronary artery compression in pulmonary hypertension Pulmonary Artery Denervation: An Alternative Therapy for Pulmonary Hypertension Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature Updated clinical classification of pulmonary hypertension Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension

Original ResearchVolume 7, Issue 6, June 2019

JOURNAL:JACC: Heart Failure Article Link

Outcomes and Effect of Treatment According to Etiology in HFrEF An Analysis of PARADIGM-HF

C Balmforth, J Simpson, L Shen et al. Keywords: angiotensin receptor blocker; angiotensin-converting enzyme inhibitor; etiology; heart failure; natriuretic peptide; sneprilysin; treatment

FULL TEXT PDF